Facing the challenges of multidrug-resistant Acinetobacter baumannii: progress and prospects in the vaccine development

References

• Vallenet D, Nordmann P, Barbe V, Poirel L, Mangenot S, Bataille E, Dossat C, Gas S, Kreimeyer A, Lenoble P, et al. Comparative analysis of acinetobacters: three genomes for three lifestyles. PLoS One. 2008;3(3):e1805. doi:10.1371/journal.pone.0001805.
   PubMed Web of Science ®Google Scholar
• Doughari HJ, Ndakidemi PA, Human IS, Benade S. The ecology, biology and pathogenesis of Acinetobacter spp.: an overview. Microbes Environ. 2011;26(2):101–12. doi:10.1264/jsme2.ME10179.
   PubMed Web of Science ®Google Scholar
• Lee CR, Lee JH, Park M, Park KS, Bae IK, Kim YB, Cha CJ, Jeong BC, Lee SH. Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol. 2017;7:55. 2235-2988 (Electronic).
   PubMed Web of Science ®Google Scholar
• Roca I, Espinal P, Vila-Farres X, Vila J. The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drug-resistant menace. Front Microbiol. 2012;3:148. 1664-302X (Electronic). doi:10.3389/fmicb.2012.00148.
   PubMed Web of Science ®Google Scholar
• Hiraki Y, Yoshida M, Masuda Y, Inoue D, Tsuji Y, Kamimura H, Karube Y, Takaki K, Kawano F. Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy. Int J Infect Dis. 2013;17(12):e1234–e1236. doi:10.1016/j.ijid.2013.05.002.
   PubMed Web of Science ®Google Scholar
• Fournier P-E, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, Richet H, Robert C, Mangenot S, Abergel C, et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet. 2006;2(1):e7. doi:10.1371/journal.pgen.0020007.
   PubMed Web of Science ®Google Scholar
• Howard A, O’Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii. Virulence. 2012;3(3):243–50. doi:10.4161/viru.19700.
   PubMed Web of Science ®Google Scholar
• Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538–82.
   PubMed Web of Science ®Google Scholar
• Mortensen E, Trivedi KK, Rosenberg J, Cody SH, Long J, Jensen BJ, Vugia DJ. Multidrug-resistant Acinetobacter baumannii infection, colonization, and transmission related to a long-term care facility providing subacute care. Infect Control Hospit Epidemiol. 2014;35(4):406–11. doi:10.1086/675612.
   PubMed Web of Science ®Google Scholar
• Sengstock M, Thyagarajan R, Apalara J, Mira A, Chopra T, Kaye KS. Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes. Clin Infect Dis. 2010;50(12):1611–16. doi:10.1086/652759.
   PubMed Web of Science ®Google Scholar
• Meumann EM, Anstey NM, Currie BJ, Piera KA, Kenyon JJ, Hall RM, Davis JS, Sarovich DS. Genomic epidemiology of severe community-onset Acinetobacter baumannii infection. Microbial Genomics. 2019;5:5. 2057-5858 (Electronic). doi:10.1099/mgen.0.000258.
   Web of Science ®Google Scholar
• CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta (GA): U.S. Department of Health and Human Services, CDC; 2019.
   Google Scholar
• Jit M, Ng DHL, Luangasanatip N, Sandmann F, Atkins KE, Robotham JV, Pouwels KB. Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies. BMC Med. 2020;18(1):38–38. doi:10.1186/s12916-020-1507-2.
   PubMed Web of Science ®Google Scholar
• Lee BY, McGlone SM, Doi Y, Bailey RR, Harrison LH. Economic impact of Acinetobacter baumannii infection in the intensive care unit. Infect Control Hospit Epidemiol. 2010;31:1087–89.
   PubMed Web of Science ®Google Scholar
• Shrestha P, Cooper BS, Coast J, Oppong R, Do Thi Thuy N, Phodha T, Celhay O, Guerin PJ, Wertheim H, Lubell Y. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. Antimicrob Resist Infect Control. 2018;7(1):98. doi:10.1186/s13756-018-0384-3.
   PubMedGoogle Scholar
• Liu L, Cui Y, Zheng B, Jiang S, Yu W, Shen P, Ji J, Li L, Qin N, Xiao Y. Analysis of tigecycline resistance development in clinical Acinetobacter baumannii isolates through a combined genomic and transcriptomic approach. Sci Rep. 2016 May 31;6:26930. doi:10.1038/srep26930.
   Web of Science ®Google Scholar
• Manchanda V, Sanchaita S, Singh N. Multidrug resistant Acinetobacter. J Glob Infect Dis. 2010;2(3):291–304. doi:10.4103/0974-777X.68538.
   PubMedGoogle Scholar
• Olaitan AO, Berrazeg M, Fagade OE, Adelowo OO, Alli JA, Rolain JM. Emergence of multidrug-resistant Acinetobacter baumannii producing oxa-23 carbapenemase, Nigeria. Int J Infect Dis. 2013;17(6):e469–e470. doi:10.1016/j.ijid.2012.12.008.
   PubMed Web of Science ®Google Scholar
• WorldHealthOrganization. WHO priority pathogens list of  R&D of new antibiotics. In: Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics; Essential Medicines and Health Products Information Portal: World Health Organization; 2017.
   Google Scholar
• Wellcome Trust. Tackling drug-resistant infections globally: final report and recommendations / the Review on Antimicrobial Resistance chaired by Jim O'Neill. Wellcome Collection. Attribution 4.0 International (CC BY 4.0).
   Google Scholar
• Makri A. Progress lags on vaccines to beat antimicrobial resistance. Lancet. 2019;394(10211):1793–94. doi:10.1016/S0140-6736(19)32758-8.
   PubMed Web of Science ®Google Scholar
• Jansen KU, Knirsch C, Anderson AS. The role of vaccines in preventing bacterial antimicrobial resistance. Nat Med. 2018;24(1):10–19. doi:10.1038/nm.4465.
   PubMed Web of Science ®Google Scholar
• Laxminarayan R, Matsoso P, Pant S, Brower C, Rottingen JA, Klugman K, Davies S. Access to effective antimicrobials: a worldwide challenge. Lancet. 2016;387:168–75. 1474-547X (Electronic). doi:10.1016/S0140-6736(15)00474-2.
   PubMed Web of Science ®Google Scholar
• Morris FC, Dexter C, Kostoulias X, Uddin MI, Peleg AY. The mechanisms of disease caused by Acinetobacter baumannii. Front Microbiol. 2019;10:1601. doi:10.3389/fmicb.2019.01601.
   PubMed Web of Science ®Google Scholar
• Abdollahi S, Rasooli I, Mousavi Gargari SL. The role of tonb-dependent copper receptor in virulence of Acinetobacter baumannii. Infect Genet Evol. 2018;60:181–90. 1567-7257 (Electronic). doi:10.1016/j.meegid.2018.03.001.
   PubMed Web of Science ®Google Scholar
• Stahl J, Bergmann H, Gottig S, Ebersberger I, Averhoff B. Acinetobacter baumannii virulence is mediated by the concerted action of three phospholipases d. PLoS One. 2015;10(9):e0138360. 1932-6203 (Electronic). doi:10.1371/journal.pone.0138360.
   PubMed Web of Science ®Google Scholar
• Dhabaan GN, AbuBakar S, Cerqueira GM, Al-Haroni M, Pang SP, Hassan H. Imipenem treatment induces expression of important genes and phenotypes in a resistant Acinetobacter baumannii isolate. Antimicrob Agents Chemother. 2015;60(3):1370–76. doi:10.1128/AAC.01696-15.
   PubMed Web of Science ®Google Scholar
• Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist. 2018;11:1249–60. doi:10.2147/IDR.S166750.
   PubMed Web of Science ®Google Scholar
• Gebhardt MJ, Gallagher LA, Jacobson RK, Usacheva EA, Peterson LR, Zurawski DV, Shuman HA. Joint transcriptional control of virulence and resistance to antibiotic and environmental stress in Acinetobacter baumannii. mBio. 2015;6(6):e01660–01615. doi:10.1128/mBio.01660-15.
   PubMed Web of Science ®Google Scholar
• Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018;16(2):91–102. doi:10.1038/nrmicro.2017.148.
   PubMed Web of Science ®Google Scholar
• Silhavy TJ, Kahne D, Walker S. The bacterial cell envelope. Cold Spring Harb Perspect Biol. 2010;2(5):a000414. doi:10.1101/cshperspect.a000414.
   PubMed Web of Science ®Google Scholar
• Skerniskyte J, Karazijaite E, Deschamps J, Krasauskas R, Armalyte J, Briandet R, Suziedeliene E. Blp1 protein shows virulence-associated features and elicits protective immunity to Acinetobacter baumannii infection. BMC Microbiol. 2019;19(1):259. doi:10.1186/s12866-019-1615-3.
   PubMed Web of Science ®Google Scholar
• Lee HW, Koh YM, Kim J, Lee JC, Lee YC, Seol SY, Cho DT, Kim J. Capacity of multidrug-resistant clinical isolates of Acinetobacter baumannii to form biofilm and adhere to epithelial cell surfaces. Clin Microbiol Infect. 2008;14(1):49–54. doi:10.1111/j.1469-0691.2007.01842.x.
   PubMed Web of Science ®Google Scholar
• Skerniskyte J, Krasauskas R, Pechoux C, Kulakauskas S, Armalyte J, Suziedeliene E. Surface-related features and virulence among Acinetobacter baumannii clinical isolates belonging to international clones i and ii. Front Microbiol. 2019;9:3116. 1664-302X (Print). doi:10.3389/fmicb.2018.03116.
   PubMed Web of Science ®Google Scholar
• Blanchard C, Barnett P, Perlmutter J, Dunman PM. Identification of Acinetobacter baumannii serum-associated antibiotic efflux pump inhibitors. Antimicrob Agents Chemother. 2014;58(11):6360–70. doi:10.1128/AAC.03535-14.
   PubMed Web of Science ®Google Scholar
• Qin H, Lo NW-S, Loo JF-C, Lin X, Yim AK-Y, Tsui SK-W, Lau TC-K, Ip M, Chan T-F. Comparative transcriptomics of multidrug-resistant Acinetobacter baumannii in response to antibiotic treatments. Sci Rep. 2018;8(1):3515. doi:10.1038/s41598-018-21841-9.
   PubMedGoogle Scholar
• Mortensen BL, Rathi S, Chazin WJ, Skaar EP. Acinetobacter baumannii response to host-mediated zinc limitation requires the transcriptional regulator zur. J Bacteriol. 2014;196(14):2616–26. doi:10.1128/JB.01650-14.
   PubMed Web of Science ®Google Scholar
• Gaddy JA, Arivett BA, McConnell MJ, Lopez-Rojas R, Pachon J, Actis LA. Role of acinetobactin-mediated iron acquisition functions in the interaction of Acinetobacter baumannii strain atcc 19606t with human lung epithelial cells, galleria mellonella caterpillars, and mice. Infect Immun. 2012;80(3):1015–24. doi:10.1128/IAI.06279-11.
   PubMed Web of Science ®Google Scholar
• Mortensen BL, Skaar EP. The contribution of nutrient metal acquisition and metabolism to Acinetobacter baumannii survival within the host. Front Cell Infect Microbiol. 2013;3:3. 2235-2988 (Print). doi:10.3389/fcimb.2013.00095.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Okujo N, Sakakibara Y. Isolation and structure elucidation of acinetobactin, a novel siderophore from Acinetobacter baumannii. Arch Microbiol. 1994;162(4):249–54. doi:10.1007/BF00301846.
   PubMed Web of Science ®Google Scholar
• Proschak A, Lubuta P, Grun P, Lohr F, Wilharm G, De Berardinis V, Bode HB. Structure and biosynthesis of fimsbactins a-f, siderophores from Acinetobacter baumannii and acinetobacter baylyi. Chembiochem. 2013;14(5):633–38. doi:10.1002/cbic.201200764.
   PubMed Web of Science ®Google Scholar
• Penwell WF, DeGrace N, Tentarelli S, Gauthier L, Gilbert CM, Arivett BA, Miller AA, Durand-Reville TF, Joubran C, Actis LA. Discovery and characterization of new hydroxamate siderophores, baumannoferrin a and b, produced by Acinetobacter baumannii. Chembiochem. 2015;16(13):1896–904. doi:10.1002/cbic.201500147.
   PubMed Web of Science ®Google Scholar
• Moynié L, Serra I, Scorciapino MA, Oueis E, Page MG, Ceccarelli M, Naismith JH. Preacinetobactin not acinetobactin is essential for iron uptake by the baua transporter of the pathogen Acinetobacter baumannii. eLife. 2018;7:e42270. doi:10.7554/eLife.42270.
   PubMed Web of Science ®Google Scholar
• Runci F, Gentile V, Frangipani E, Rampioni G, Leoni L, Lucidi M, Visaggio D, Harris G, Chen W, Stahl J, et al. Contribution of active iron uptake to Acinetobacter baumannii pathogenicity. Infect Immun. 2019;87(4). doi:10.1128/IAI.00755-18.
   PubMed Web of Science ®Google Scholar
• Modarresi F, Azizi O, Shakibaie MR, Motamedifar M, Valibeigi B, Mansouri S. Effect of iron on expression of efflux pump (adeABC) and quorum sensing (luxi, luxr) genes in clinical isolates of Acinetobacter baumannii. APMIS. 2015;123(11):959–68. doi:10.1111/apm.12455.
   PubMed Web of Science ®Google Scholar
• Tiwari V, Rajeswari MR, Tiwari M. Proteomic analysis of iron-regulated membrane proteins identify fhue receptor as a target to inhibit siderophore-mediated iron acquisition in Acinetobacter baumannii. Int J Biol Macromol. 2019;125:1156–67. doi:10.1016/j.ijbiomac.2018.12.173.
   PubMed Web of Science ®Google Scholar
• McConnell MJ, Pachon J. Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine. 2010;29:1–5. 1873-2518 (Electronic). doi:10.1016/j.vaccine.2010.10.052.
   PubMed Web of Science ®Google Scholar
• Bentancor LV, O’Malley JM, Bozkurt-Guzel C, Gb P, Maira-Litrán T. Poly-n-acetyl-beta-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections. Infect Immun. 2012;80:651–56. 1098-5522 (Electronic). doi:10.1128/IAI.05653-11.
   PubMed Web of Science ®Google Scholar
• Shu MH, MatRahim N, NorAmdan N, Pang SP, Hashim SH, Phoon WH, AbuBakar S. An inactivated antibiotic-exposed whole-cell vaccine enhances bactericidal activities against multidrug-resistant Acinetobacter baumannii. Sci Rep. 2016;6:22332. 2045-2322 (Electronic). doi:10.1038/srep22332.
   PubMed Web of Science ®Google Scholar
• Sheweita SA, Batah AM, Ghazy AA, Hussein A, Amara AA. A new strain of Acinetobacter baumannii and characterization of its ghost as a candidate vaccine. J Infect Public Health. 2019;12(6):831–42. doi:10.1016/j.jiph.2019.05.009.
   PubMed Web of Science ®Google Scholar
• Das S, Mohakud NK, Suar M, Sahu BR. Vaccine development for enteric bacterial pathogens: where do we stand? Pathog Dis. 2018;76(5). doi:10.1093/femspd/fty057.
   PubMed Web of Science ®Google Scholar
• McConnell MJ, Dominguez-Herrera J, Smani Y, Lopez-Rojas R, Docobo-Perez F, Pachon J. Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii. Infect Immun. 2011;79(1):518–26. doi:10.1128/IAI.00741-10.
   PubMed Web of Science ®Google Scholar
• McConnell MJ, Rumbo C, Bou G, Pachón J. Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. Vaccine. 2011;29:5705–10.
   PubMed Web of Science ®Google Scholar
• Huang W, Yao Y, Long Q, Yang X, Sun W, Liu C, Jin X, Li Y, Chu X, Chen B, et al. Immunization against multidrug-resistant Acinetobacter baumannii effectively protects mice in both pneumonia and sepsis models. PLoS One. 2014;9:e100727. 1932-6203 (Electronic). doi:10.1371/journal.pone.0100727.
   PubMed Web of Science ®Google Scholar
• Pulido MR, Garcia-Quintanilla M, Pachon J, McConnell MJ. Immunization with lipopolysaccharide-free outer membrane complexes protects against Acinetobacter baumannii infection. Vaccine. 2018;36(29):4153–56. doi:10.1016/j.vaccine.2018.05.113.
   PubMed Web of Science ®Google Scholar
• Garcia-Quintanilla M, Pulido MR, Pachon J, McConnell MJ. Immunization with lipopolysaccharide-deficient whole cells provides protective immunity in an experimental mouse model of Acinetobacter baumannii infection. PLoS One. 2014;9(12):e114410. doi:10.1371/journal.pone.0114410.
   PubMed Web of Science ®Google Scholar
• Pulido MR, Garcia-Quintanilla M, Pachon J, McConnell MJ. A lipopolysaccharide-free outer membrane vesicle vaccine protects against Acinetobacter baumannii infection. Vaccine. 2020;38(4):719–24. doi:10.1016/j.vaccine.2019.11.043.
   PubMed Web of Science ®Google Scholar
• Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, Michael FS, Cox AD, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother. 2010;54:4971–77. 1098-6596 (Electronic). doi:10.1128/AAC.00834-10.
   PubMed Web of Science ®Google Scholar
• Miquel-Clopes A, Bentley EG, Stewart JP, Carding SR. Mucosal vaccines and technology. Clin Exp Immunol. 2019;196(2):205–14. doi:10.1111/cei.13285.
   PubMed Web of Science ®Google Scholar
• Micoli F, Costantino P, Adamo R. Potential targets for next generation antimicrobial glycoconjugate vaccines. FEMS Microbiol Rev. 2018;42:388–423.
   PubMed Web of Science ®Google Scholar
• Micoli F, Del Bino L, Alfini R, Carboni F, Romano MR, Adamo R. Glycoconjugate vaccines: current approaches towards faster vaccine design. Expert Rev Vaccines. 2019;18(9):881–95. doi:10.1080/14760584.2019.1657012.
   PubMed Web of Science ®Google Scholar
• Russo TA, Beanan JM, Olson R, MacDonald U, Cox AD, Michael FS, Vinogradov EV, Spellberg B, Luke-Marshall NR, Campagnari AA. The k1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun. 2013;81:915–22. 1098-5522 (Electronic). doi:10.1128/IAI.01184-12.
   PubMed Web of Science ®Google Scholar
• Chen W. Current advances and challenges in the development of acinetobacter vaccines. Hum Vaccin Immunother. 2015;11(10):2495–500. doi:10.1080/21645515.2015.1052354.
   PubMed Web of Science ®Google Scholar
• Singh JK, Adams FG, Brown MH. Diversity and function of capsular polysaccharide in Acinetobacter baumannii. Front Microbiol. 2018;9:3301. doi:10.3389/fmicb.2018.03301.
   PubMed Web of Science ®Google Scholar
• Ahmad TA, Tawfik DM, Sheweita SA, Haroun M, El-Sayed LH. Development of immunization trials against Acinetobacter baumannii. Trials Vaccinol. 2016;5:53–60. doi:10.1016/j.trivac.2016.03.001.
   Google Scholar
• Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond). 2007;57(8):552–56. doi:10.1093/occmed/kqm110.
   PubMed Web of Science ®Google Scholar
• Nie D, Hu Y, Chen Z, Li M, Hou Z, Luo X, Mao X, Xue X. Outer membrane protein a (ompa) as a potential therapeutic target for Acinetobacter baumannii infection. J Biomed Sci. 2020;27(1):26. doi:10.1186/s12929-020-0617-7.
   PubMed Web of Science ®Google Scholar
• Luo G, Lin L, Ibrahim AS, Baquir B, Pantapalangkoor P, Bonomo RA, Doi Y, Adams MD, Russo TA, Spellberg B. Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS One. 2012;7:e29446.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yang T, Cao J, Sun J, Dai W, Zhang L. Mucosal immunization with purified OmpA elicited protective immunity against infections caused by multidrug-resistant Acinetobacter baumannii. Microb Pathog. 2016;96:20–25. 1096-1208 (Electronic). doi:10.1016/j.micpath.2016.04.019.
   PubMed Web of Science ®Google Scholar
• Ansari H, Tahmasebi-Birgani M, Bijanzadeh M, Doosti A, Kargar M. Study of the immunogenicity of outer membrane protein a (OmpA) gene from Acinetobacter baumannii as DNA vaccine candidate in vivo. Iran J Basic Med Sci. 2019;22(6):669–75. doi:10.22038/ijbms.2019.30799.7427.
   PubMed Web of Science ®Google Scholar
• Lei L, Yang F, Zou J, Jing H, Zhang J, Xu W, Zou Q, Zhang J, Wang X. DNA vaccine encoding ompa and pal from Acinetobacter baumannii efficiently protects mice against pulmonary infection. Mol Biol Rep. 2019;46(5):5397–408. doi:10.1007/s11033-019-04994-2.
   PubMed Web of Science ®Google Scholar
• Viale AM, Evans BA. Microevolution in the major outer membrane protein OmpA of Acinetobacter baumannii. Microb Genom. 2020:6(6).
   Google Scholar
• Huang W, Yao Y, Wang S, Xia Y, Yang X, Long Q, Sun W, Liu C, Li Y, Chu X, et al. Immunization with a 22-kda outer membrane protein elicits protective immunity to multidrug-resistant Acinetobacter baumannii. Sci Rep. 2016;6:20724. 2045-2322 (Electronic). doi:10.1038/srep20724.
   PubMed Web of Science ®Google Scholar
• Singh R, Capalash N, Sharma P. Immunoprotective potential of bama, the outer membrane protein assembly factor, against MDR Acinetobacter baumannii. Sci Rep. 2017;7(1):12411. doi:10.1038/s41598-017-12789-3.
   PubMed Web of Science ®Google Scholar
• Wang-Lin SX, Olson R, Beanan JM, MacDonald U, Balthasar JP, Russo TA. The capsular polysaccharide of Acinetobacter baumannii is an obstacle for therapeutic passive immunization strategies. Infect Immun. 2017;85(12). doi:10.1128/IAI.00591-17.
   PubMed Web of Science ®Google Scholar
• Bentancor LV, Routray A, Bozkurt-Guzel C, Camacho-Peiro A, Pier GB, Maira-Litrán T. Evaluation of the trimeric autotransporter ata as a vaccine candidate against Acinetobacter baumannii infections. Infect Immun. 2012;80:3381–88. 1098-5522 (Electronic). doi:10.1128/IAI.06096-11.
   PubMed Web of Science ®Google Scholar
• Weidensdorfer M, Ishikawa M, Hori K, Linke D, Djahanschiri B, Iruegas R, Ebersberger I, Riedel-Christ S, Enders G, Leukert L, et al. The acinetobacter trimeric autotransporter adhesin ata controls key virulence traits of Acinetobacter baumannii. Virulence. 2019;10(1):68–81. doi:10.1080/21505594.2018.1558693.
   PubMed Web of Science ®Google Scholar
• Li H, Tan H, Hu Y, Pan P, Su X, Hu C. Small protein a and phospholipase d immunization serves a protective role in a mouse pneumonia model of Acinetobacter baumannii infection. Mol Med Rep. 2017;16(2):1071–78. doi:10.3892/mmr.2017.6688.
   PubMed Web of Science ®Google Scholar
• Hubert K, Devos N, Mordhorst I, Tans C, Baudoux G, Feron C, Goraj K, Tommassen J, Vogel U, Poolman JT, et al. Znud, a potential candidate for a simple and universal neisseria meningitidis vaccine. Infect Immun. 2013;81(6):1915–27. doi:10.1128/IAI.01312-12.
   PubMed Web of Science ®Google Scholar
• Qamsari MM, Rasooli I, Chaudhuri S, Astaneh SDA, Schryvers AB. Hybrid antigens expressing surface loops of znud from Acinetobacter baumannii is capable of inducing protection against infection. Front Immunol. 2020;11:158–158. doi:10.3389/fimmu.2020.00158.
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Reverse vaccinology. Curr Opin Microbiol. 2000;3:445–50. 1369-5274 (Print). doi:10.1016/S1369-5274(00)00119-3.
   PubMed Web of Science ®Google Scholar
• Singh R, Garg N, Shukla G, Capalash N, Sharma P. Immunoprotective efficacy of Acinetobacter baumannii outer membrane protein, filf, predicted in silico as a potential vaccine candidate. Front Microbiol. 2016;7. 1664-302X (Print). doi:10.3389/fmicb.2016.00158.
   Web of Science ®Google Scholar
• Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity. 2010;33(4):530–41. doi:10.1016/j.immuni.2010.09.017.
   PubMed Web of Science ®Google Scholar
• Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup b, 4cmenb: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30(Suppl 2):B87–97. 1873-2518 (Electronic). doi:10.1016/j.vaccine.2012.01.033.
   PubMed Web of Science ®Google Scholar
• Ni Z, Chen Y, Ong E, He Y. Antibiotic resistance determinant-focused Acinetobacter baumannii vaccine designed using reverse vaccinology. Int J Mol Sci. 2017;18:E458. 1422-0067 (Electronic). doi:10.3390/ijms18020458.
   PubMed Web of Science ®Google Scholar
• Chiang MH, Sung WC, Lien SP, Chen YZ, Lo AFY, Huang JH, Kuo SC, Chong P. Identification of novel vaccine candidates against Acinetobacter baumannii using reverse vaccinology. Hum Vaccin Immunother. 2015;11:1065–73. 2164-554X (Electronic). doi:10.1080/21645515.2015.1010910.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Azam SS. A novel approach of virulome based reverse vaccinology for exploring and validating peptide-based vaccine candidates against the most troublesome nosocomial pathogen: Acinetobacter baumannii. J Mol Graph Model. 2018;83:1–11. 1873-4243 (Electronic). doi:10.1016/j.jmgm.2018.04.020.
   PubMed Web of Science ®Google Scholar
• Solanki V, Tiwari V. Subtractive proteomics to identify novel drug targets and reverse vaccinology for the development of chimeric vaccine against Acinetobacter baumannii. Sci Rep. 2018;8(1):9044. doi:10.1038/s41598-018-26689-7.
   PubMed Web of Science ®Google Scholar
• Tapia-Calle G, Stoel M, de Vries-idema J, Huckriede A. Distinctive responses in an in vitro human dendritic cell-based system upon stimulation with different influenza vaccine formulations. Vaccine. 2017;5:E21. 2076-393X (Print).
   Web of Science ®Google Scholar
• Stech M, Nikolaeva O, Thoring L, Stocklein WFM, Wustenhagen DA, Hust M, Dubel S, Kubick S. Cell-free synthesis of functional antibodies using a coupled in vitro transcription-translation system based on cho cell lysates. Sci Rep. 2017;7:12030. 2045-2322 (Electronic). doi:10.1038/s41598-017-12364-w.
   PubMed Web of Science ®Google Scholar
• Dilworth MV, Piel MS, Bettaney KE, Ma P, Luo J, Sharples D, Poyner DR, Gross SR, Moncoq K, Henderson PJF, et al. Microbial expression systems for membrane proteins. Methods. 2018;147:3–39. doi:10.1016/j.ymeth.2018.04.009.
   PubMed Web of Science ®Google Scholar
• Fakruddin M, Mohammad Mazumdar R, Bin Mannan KS, Chowdhury A, Hossain MN. Critical factors affecting the success of cloning, expression, and mass production of enzymes by recombinant E. coli. ISRN Biotechnol. 2013;2013:590587. doi:10.5402/2013/590587.
   PubMedGoogle Scholar
• Rosano GL, Ceccarelli EA. Recombinant protein expression in escherichia coli: advances and challenges. Front Microbiol. 2014;5:172. 1664-302X (Print). doi:10.3389/fmicb.2014.00172.
   PubMed Web of Science ®Google Scholar
• Jahangiri A, Rasooli I, Owlia P, Fooladi AAI, Salimian J. An integrative in silico approach to the structure of omp33-36 in Acinetobacter baumannii. Comput Biol Chem. 2018;72:77–86. 1476–928X (Electronic). doi:10.1016/j.compbiolchem.2018.01.003.
   PubMed Web of Science ®Google Scholar
• Gefen T, Vaya J, Khatib S, Rapoport I, Lupo M, Barnea E, Admon A, Heller ED, Aizenshtein E, Pitcovski J. The effect of haptens on protein-carrier immunogenicity. Immunology. 2015;144(1):116–26. doi:10.1111/imm.12356.
   PubMed Web of Science ®Google Scholar
• Meyer H, Schmidhalter D. Microbial Expression Systems and Manufacturing from a Market and Economic Perspective, Innovations in Biotechnology. In: Dr. Eddy C. Agbo editor. InTech. ISBN: 978-953-51- 0096-6. Available from: http://www.intechopen.com/books/innovations-in-biotechnology/microbialexpression-systems-and-manufacturing-from-a-market-and-economic-perspective.
   Google Scholar
• White J. Protein expression in corynebacterium glutamicum. Bioprocess J. 2011;9:53–55. doi:10.12665/J92.White.
   Google Scholar
• Tavares Batista M, Souza RD, Paccez JD, Luiz WB, Ferreira EL, Cavalcante RCM, Ferreira RCC, Ferreira LCS. Gut adhesive bacillus subtilis spores as a platform for mucosal delivery of antigens. Infect Immun. 2014;82(4):1414–23. doi:10.1128/IAI.01255-13.
   PubMed Web of Science ®Google Scholar
• Lefevre M, Racedo SM, Ripert G, Housez B, Cazaubiel M, Maudet C, Justen P, Marteau P, Urdaci MC. Probiotic strain bacillus subtilis cu1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. Immun Ageing. 2015;12:24. doi:10.1186/s12979-015-0051-y.
   PubMed Web of Science ®Google Scholar
• Rosales-Mendoza S, Angulo C. Bacillus subtilis comes of age as a vaccine production host and delivery vehicle. Expert Rev Vaccines. 2015;4:1135–48. 1744–8395 (Electronic).
   Google Scholar
• Wenzel M, Muller A, Siemann-Herzberg M, Altenbuchner J. Self-inducible bacillus subtilis expression system for reliable and inexpensive protein production by high-cell-density fermentation. Appl Environ Microbiol. 2011;77(18):6419–25. doi:10.1128/AEM.05219-11.
   PubMed Web of Science ®Google Scholar
• Copland A, Diogo GR, Hart P, Harris S, Tran AC, Paul MJ, Singh M, Cutting SM, Reljic R. Mucosal delivery of fusion proteins with bacillus subtilis spores enhances protection against tuberculosis by Bacillus calmette-guérin. Front Immunol. 2018;9:346. doi:10.3389/fimmu.2018.00346.
   PubMed Web of Science ®Google Scholar
• Sun H, Lin Z, Zhao L, Chen T, Shang M, Jiang H, Tang Z, Zhou X, Shi M, Zhou L, et al. Bacillus subtilis spore with surface display of paramyosin from clonorchis sinensis potentializes a promising oral vaccine candidate. Parasit Vectors. 2018;11(1):156. doi:10.1186/s13071-018-2757-0.
   PubMedGoogle Scholar
• Sibley L, Reljic R, Radford DS, Huang J-M, Hong HA, Cranenburgh RM, Cutting SM. Recombinant bacillus subtilis spores expressing mpt64 evaluated as a vaccine against tuberculosis in the murine model. FEMS Microbiol Lett. 2014;358(2):170–79. doi:10.1111/1574-6968.12525.
   PubMed Web of Science ®Google Scholar
• Yan Z, Yang J, Hu R, Hu X, Chen K. Acinetobacter baumannii infection and il-17 mediated immunity. Mediators Inflamm. 2016;2016:9834020. doi:10.1155/2016/9834020.
   PubMed Web of Science ®Google Scholar
• Erridge C, Moncayo-Nieto OL, Morgan R, Young M, Poxton IR. Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via toll-like receptor 4 signalling. J Med Microbiol. 2007;56:165–71. 0022-2615 (Print). doi:10.1099/jmm.0.46823-0.
   PubMed Web of Science ®Google Scholar
• Peck A, Mellins ED. Precarious balance: Th17 cells in host defense. Infect Immun. 2010;78(1):32–38. doi:10.1128/IAI.00929-09.
   PubMed Web of Science ®Google Scholar
• Wang S, Liu H, Zhang X, Qian F. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell. 2015;6(7):480–503. doi:10.1007/s13238-015-0164-2.
   PubMed Web of Science ®Google Scholar
• Rhayat L, Maresca M, Nicoletti C, Perrier J, Brinch KS, Christian S, Devillard E, Eckhardt E. Effect of bacillus subtilis strains on intestinal barrier function and inflammatory response. Front Immunol. 2019;10:564. doi:10.3389/fimmu.2019.00564.
   PubMed Web of Science ®Google Scholar
• Jacobs AC, Thompson MG, Black CC, Kessler JL, Clark LP, McQueary CN, Gancz HY, Corey BW, Moon JK, Si Y, et al. Ab5075, a highly virulent isolate of Acinetobacter baumannii, as a model strain for the evaluation of pathogenesis and antimicrobial treatments. mBio. 2014;5(3):e01076–01014. doi:10.1128/mBio.01076-14.
   PubMed Web of Science ®Google Scholar
• Harris G, Kuo Lee R, Lam CK, Kanzaki G, Patel GB, Xu HH, Chen W. A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain. Antimicrob Agents Chemother. 2013;57(8):3601–13. doi:10.1128/AAC.00944-13.
   PubMed Web of Science ®Google Scholar
• Luo G, Spellberg B, Gebremariam T, Bolaris M, Lee H, Fu Y, French SW, Ibrahim AS. Diabetic murine models for Acinetobacter baumannii infection. J Antimicrob Chemother. 2012;67(6):1439–45. doi:10.1093/jac/dks050.
   PubMed Web of Science ®Google Scholar
• Luna BM, Yan J, Reyna Z, Moon E, Nielsen TB, Reza H, Lu P, Bonomo R, Louie A, Drusano G, et al. Natural history of Acinetobacter baumannii infection in mice. PLOS ONE. 2019;14(7):e0219824. doi:10.1371/journal.pone.0219824.
   PubMed Web of Science ®Google Scholar
• Harris G, KuoLee R, Xu HH, Chen W. Acute intraperitoneal infection with a hypervirulent Acinetobacter baumannii isolate in mice. Sci Rep. 2019;9(1):6538. doi:10.1038/s41598-019-43000-4.
   PubMed Web of Science ®Google Scholar
• McConnell MJ, Actis L, Pachon J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev. 2013;37(2):130–55. doi:10.1111/j.1574-6976.2012.00344.x.
   PubMed Web of Science ®Google Scholar
• Qiu H, KuoLee R, Harris G, Chen W. High susceptibility to respiratory Acinetobacter baumannii infection in A/J mice is associated with a delay in early pulmonary recruitment of neutrophils. Microbes Infect. 2009;11(12):946–55. doi:10.1016/j.micinf.2009.06.003.
   PubMed Web of Science ®Google Scholar
• Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiological overview of acinetobacter infections: a century of challenges. Clin Microbiol Rev. 2017;30:409–47.
   PubMed Web of Science ®Google Scholar
• Russo TA, Beanan JM, Olson R, MacDonald U, Luke NR, Gill SR, Campagnari AA. Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology. Infect Immun. 2008;76(8):3577–86. doi:10.1128/IAI.00269-08.
   PubMed Web of Science ®Google Scholar
• WellcomeTrust, BostonConsultingGroup. Vaccines to tackle drug-resistant infections: An evaluation of R&D opportunities.[Online]. https://vaccinesforamr.org/wp-content/uploads/2018/09/Vaccines_for_AMR.pdf
   Google Scholar
• Weinberger B. Vaccines for the elderly: current use and future challenges. Immun Ageing. 2018;15:3. doi:10.1186/s12979-017-0107-2.
   PubMed Web of Science ®Google Scholar
• Gu H, Liu D, Zeng X, Peng LS, Yuan Y, Chen ZF, Zou QM, Shi Y. Aging exacerbates mortality of Acinetobacter baumannii pneumonia and reduces the efficacies of antibiotics and vaccine. Aging. 2018;10(7):1597–608. doi:10.18632/aging.101495.
   PubMedGoogle Scholar
• Chen WH, Kozlovsky BF, Effros RB, Grubeck-Loebenstein B, Edelman R, Sztein MB. Vaccination in the elderly: an immunological perspective. Trends Immunol. 2009;30(7):351–59. doi:10.1016/j.it.2009.05.002.
   PubMed Web of Science ®Google Scholar
• Whitman TJ, Qasba SS, Timpone JG, Babel BS, Kasper MR, English JF, Sanders JW, Hujer KM, Hujer AM, Endimiani A, et al. Occupational transmission of Acinetobacter baumannii from a united states serviceman wounded in iraq to a health care worker. Clin Infect Dis. 2008;47(4):439–43. doi:10.1086/589247.
   PubMed Web of Science ®Google Scholar
• Sacadura-Leite E, Mendonça-Galaio L, Shapovalova O, Pereira I, Rocha R, Sousa-Uva A. Biological hazards for healthcare workers: occupational exposure to vancomycin-resistant staphylococcus aureus as an example of a new challenge. Portuguese J Public Health. 2018;36(1):26–31. doi:10.1159/000487746.
   Google Scholar
• Gruenheid S, Gros P. Forward genetic dissection of innate response to infection in inbred mouse strains: selected success stories. Clin Exp Immunol. 2010;162(3):393–401. doi:10.1111/j.1365-2249.2010.04249.x.
   PubMed Web of Science ®Google Scholar